FYERS
Vista Pharmaceuticals5.87
-0.01 (-0.17%)

Vista Pharmaceuticals Share Price

5.87-0.01 (-0.17%)
-38.21% past 1 Year

Corporate filings & documents

Announcements

Resignation of Company Secretary & Compliance Officer
1 week ago
Resignation of Company Secretary & Compliance Officer
1 week ago
Results for the quarter ended 30.06.2026
1 month ago
Results for the quarter ended 30.06.2026
1 month ago
Results for the quarter ended 30.06.2026
1 month ago
Results for the quarter ended 30.06.2026
1 month ago
Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 inter alia to consider and approve 1. Unaudited financial results for the quarter ended 30.06.20262. Limited Review Report for the quarter ended 30.06.20263. Any other business with the permission of the Chair.
1 month ago
Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 inter alia to consider and approve 1. Unaudited financial results for the quarter ended 30.06.20262. Limited Review Report for the quarter ended 30.06.20263. Any other business with the permission of the Chair.
1 month ago
Compliance - Certificate under Reg 74(5) of SEBI (DP)regulations 2018
2 months ago
Compliance - Certificate under Reg 74(5) of SEBI (DP)regulations 2018
2 months ago
Closure of Trading window
2 months ago
Closure of Trading window
2 months ago
SEBI Secretarial Compliance Report for the year ended 31.03.2026
3 months ago
Board meeting outcome
3 months ago
Board meeting outcome
3 months ago
Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 inter alia to consider and approve 1. Audited financial results for the quarter and year ended 31.03.20262. Audit Report for the quarter and year ended 31.03.20263. Any other business with the permission of the Chair.
4 months ago
Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 inter alia to consider and approve 1. Audited financial results for the quarter and year ended 31.03.20262. Audit Report for the quarter and year ended 31.03.20263. Any other business with the permission of the Chair.
4 months ago
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Vista Pharmaceuticals Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L24239TG1991PLC012264</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>2025-26 2026-27</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>2024-25 2025-26</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>Barka Jain</td></tr><tr><td>Designation :-</td><td>Company Secretary compliance Officer</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>Suneel pachipala</td></tr> <tr><td>Designation : -</td><td>CFO</td></tr></table><div> <br/> Date: 29/04/2026<br/><br/></div>
4 months ago
Compliance - certificate under Reg. 74(5) of SEBI (DP) Regulations 2018
5 months ago
Closure of Trading Window
5 months ago
Closure of Trading Window
5 months ago
Un audited Financial Results for the quarter ended 31.12.2025
7 months ago
Un audited Financial Results for the quarter ended 31.12.2025
7 months ago
Results for the quarter ended 31.12.2025
7 months ago
Results for the quarter ended 31.12.2025
7 months ago
The Board Meeting to be held on 23/02/2026 has been revised to 13/02/2026 The Board Meeting to be held on 23/02/2026 has been revised to 13/02/2026
7 months ago
Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/02/2026 inter alia to consider and approve 1. Unaudited financial results for the quarter and nine months ended 31.12.2025.2. Limited Review Report quarter and nine months 31.12.2025.3. Any other business with the permission of the Chair.
7 months ago
Disclosure
7 months ago
Compliance - Certificate under Reg 74(5) of SEBI (DP) Regulations
8 months ago
Closure of Trading Window
8 months ago
Un audited financial Results for the quarter and half year ended 30.09.2025
10 months ago
Un audited Financials Results for the quarter and half year ended 30.09.2025
10 months ago
Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 inter alia to consider and approve 1. Unaudited financial results for the quarter ended 30.09.2025.2. Limited Review Report for quarter ended 30.09.2025.3. Any other business with the permission of the Chair.
10 months ago
Compliance - certificate under Reg. 74(5) of SEBI (DP) Regulations 2018
11 months ago
Scrutinizers report and Outcome of AGM
11 months ago
Outcome of AGM of Vista Pharmaceutical Limited held on 30.09.2025
11 months ago
Closure of Trading Window under SEBI (Prohibition of Insider Trading Regulations) 2015
12 months ago

Annual reports

FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21

Concalls & investor presentations

Empty box

No presentations found

Vista Pharmaceuticals Ltd Share Price Today

The Vista Pharmaceuticals Ltd share price today is ₹6.38. During the trading session, the Vista Pharmaceuticals Ltd share price opened at ₹6.48 and recorded an intraday high of ₹6.48 and a low of ₹6.28. Last closing price was ₹6.28. Over the past 52 weeks, the Vista Pharmaceuticals Ltd share price has ranged between ₹5.71 and ₹10.75. The current Vista Pharmaceuticals Ltd stock price reflects real-time market activity based on executed trades on the exchange.